Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Rachel O. Abelman, Aditya Bardia, Steven J. Isakoff et al.|Journal of Clinical Oncology|2023Cited by 53
Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Mark N. Melkonyan et al.|Clinical Cancer Research|2024Cited by 43
Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker AnalysisRachel O. Abelman, Aditya Bardia, Steven J. Isakoff et al.|Cancer Research|2024Cited by 21
TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysisArielle J. Medford, Aditya Bardia, Lesli A. Kiedrowski et al.|Therapeutic Advances in Medical Oncology|2023Cited by 11
Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast CancerRachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Hematology/Oncology Clinics of North America|2022Cited by 4